E-drug: How Increased Competition from Generic Drugs Has Affected Prices
and Returns in the Pharmaceutical Industry
[copied from list IP-HEALTH <ip-health@essential.org>]
In July 1998 the Congressional Budget Office (CBO) published a report
called "How Increased Competition from Generic Drugs Has Affected Prices
and Returns in the Pharmaceutical Industry".
One conclusion of the report is that, in one year (1994), american
consumers saved $ 8-10 billion because of generic drugs.
It contains more than 15 tables with very interesting datas such as
price comparison between generics and brand drugs, market shares between
generics and brand durgs, etc...
The report examines also the issue of pricing and competition in the
phamrmaceutical market, or the effects of the Hatch-Waxman Act on the
returns from innovation. It takes position against a possible amendment
of the Hatch-Waxman Act to lengthen patent-term extensions.
This report is available on the web at:
http://www.cbo.gov/showdoc.cfm?index=655&sequence=0&from=1
Catherine Gavin
Email: <cgavin@cptech.org>
--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.